Maci 3CM x 5CM implant sheets
Ended Awarded Last action
- Contract number
- SPE2DR26FKAR5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $63,176
Award facts
- Contract value 100% obligated
- $63,175.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $63,175.92 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for MACI 3 cm x 5 cm implant sheets. The contract, issued on December 30, 2025, with an ultimate completion date of January 22, 2026, operates under a firm fixed-price structure with no set-aside designation, allowing the vendor to compete in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036.
The PPV-G GEN V program represents a $30.3 billion acquisition strategy designed to provide the Department of Defense with a comprehensive range of pharmaceutical products and medical consumables to support military healthcare facilities worldwide. DMS Pharmaceutical Group's product portfolio spans branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical devices, positioning the company as a critical supplier within the federal pharmaceutical supply chain. The MACI implant sheets being procured under this delivery order are specialty surgical products used in orthopedic and regenerative medicine applications, reflecting the vendor's established capability to fulfill the diverse and specialized pharmaceutical and medical supply requirements of the Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FKAR5?
SPE2DR26FKAR5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 30, 2025.
How much is contract SPE2DR26FKAR5 worth?
The government has obligated $63,176 on SPE2DR26FKAR5.
Is contract SPE2DR26FKAR5 an order under another contract?
Yes. SPE2DR26FKAR5 is a delivery order under SPE2DR25D9365, an indefinite delivery contract.
Was contract SPE2DR26FKAR5 competed?
The extent of competition for SPE2DR26FKAR5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award